Context Therapeutics Ownership | Who Owns Context Therapeutics?


OverviewForecastFinancialsChart

Context Therapeutics Ownership Summary


Context Therapeutics is owned by 3.92% institutional investors, 2.27% insiders, and 93.81% retail investors. Bioimpact capital is the largest institutional shareholder, holding 15.45% of CNTX shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.48% of its assets in Context Therapeutics shares.

CNTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockContext Therapeutics3.92%2.27%93.81%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bioimpact capital14.71M15.45%$14.25M
Avidity partners management lp8.98M9.44%$8.70M
Nextech invest7.42M9.22%$7.79M
Nextech invest7.42M7.79%$7.19M
Deep track capital, lp7.42M7.79%$7.19M
Blue owl capital lp7.41M7.78%$7.18M
Blackrock851.70K5.33%$1.71M
Great point partners4.68M4.92%$4.54M
Franklin resources4.00M4.21%$3.88M
Vanguard group3.50M3.67%$3.39M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bioimpact capital14.71M2.33%$14.25M
Blue owl capital lp7.41M2.23%$7.18M
Avidity partners management lp8.98M1.98%$8.70M
Great point partners4.68M1.87%$4.54M
Nextech invest7.42M1.26%$7.79M
Nextech invest7.42M1.09%$7.19M
Sio capital management1.34M0.33%$1.30M
Deep track capital, lp7.42M0.20%$7.19M
Velan capital investment management lp100.00K0.09%$96.88K
Caxton18.40K0.08%$17.83K

Top Buyers

HolderShares% AssetsChange
Avidity partners management lp8.98M1.98%1.50M
Blackrock851.70K-851.70K
Vanguard group3.50M0.00%134.45K
Pathstone110.24K0.00%110.24K
Marshall wace, llp35.75K-35.75K

Top Sellers

HolderShares% AssetsChange
Driehaus capital management---2.26M
Ally bridge group (ny)---1.16M
Opaleye management---1.11M
Allostery investments lp---950.17K
Woodline partners lp---680.19K

New Positions

HolderShares% AssetsChangeValue
Blackrock851.70K-851.70K$1.71M
Pathstone110.24K0.00%110.24K$106.80K
Marshall wace, llp35.75K-35.75K$34.68K
Acadian asset management16.67K-16.67K$17.00K
Barclays167.00-167.00$162.00

Sold Out

HolderChange
Jpmorgan chase-80.00
Wells fargo & company/mn-116.00
Advisornet financial-200.00
Federation des caisses desjardins du quebec-400.00
Newbridge financial services group-2.00K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20255-87.18%3,733,804-94.56%30.08%3-76.92%--100.00%
Jun 30, 202539-9.30%68,619,080-3.91%721.28%1220.00%9-35.71%
Mar 31, 20259-82.69%31,512,715-56.71%330.40%--100.00%1-91.67%
Dec 31, 20245223.81%72,787,03428.41%901.82%2833.33%1220.00%
Sep 30, 20244223.53%56,682,696-0.62%700.65%21-22.22%10233.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF3.12M3.48%-6.75K
Vanguard Total Stock Mkt Idx Inv2.55M2.84%-55.73K
Franklin Biotechnology Discv A(acc)USD2.52M2.81%-
Franklin Biotechnology Discovery A1.48M1.65%-
Vanguard Institutional Extnd Mkt Idx Tr520.90K0.58%-156.91K
Fidelity Extended Market Index282.37K0.31%-2.32K
Calamos Market Neutral Income A277.81K0.31%-
Belfund SICAV Belinvest Equity A USD Acc260.00K0.29%-
BlackRock Extended Equity Market K104.84K0.14%-45.00
Extended Equity Market Fund K101.71K0.11%-2.03K

Recent Insider Transactions


DateNameRoleActivityValue
Jun 09, 2025Lehr Martin A. Chief Executive OfficerBuy$70.08K
Jun 06, 2025Levit Alex C. Chief Legal Officer, Corp. SecBuy$11.52K
Jun 06, 2025Minai-Azary Jennifer Lynn Chief Financial OfficerBuy$25.49K
Feb 21, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K
Feb 13, 2023Lehr Martin A. Chief Executive OfficerBuy$4.90K

Insider Transactions Trends


DateBuySell
2025 Q23-
2025 Q1--
2024 Q3--
2024 Q2--
2024 Q1--

CNTX Ownership FAQ


Who Owns Context Therapeutics?

Context Therapeutics shareholders are primarily institutional investors at 3.92%, followed by 2.27% insiders and 93.81% retail investors. The average institutional ownership in Context Therapeutics's industry, Biotech Stocks , is 45.24%, which Context Therapeutics falls below.

Who owns the most shares of Context Therapeutics?

Context Therapeutics’s largest shareholders are Bioimpact capital (14.71M shares, 15.45%), Avidity partners management lp (8.98M shares, 9.44%), and Nextech invest (7.42M shares, 9.22%). Together, they hold 34.10% of Context Therapeutics’s total shares outstanding.

Does Blackrock own Context Therapeutics?

Yes, BlackRock owns 5.33% of Context Therapeutics, totaling 851.7K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.71M$. In the last quarter, BlackRock increased its holdings by 851.7K shares, a 100.00% change.

Who is Context Therapeutics’s biggest shareholder by percentage of total assets invested?

Bioimpact capital is Context Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.33% of its assets in 14.71M Context Therapeutics shares, valued at 14.25M$.

Who is the top mutual fund holder of Context Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Context Therapeutics shares, with 3.48% of its total shares outstanding invested in 3.12M Context Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools